Creative Medical Technology Holdings (CELZ) Intangibles (2016 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Intangibles of $407230.0 for Q4 2025, down 23.25% year-over-year from $530559.0 in Q4 2024, and up 1268.98% quarter-over-quarter from $29747.0 in Q3 2025.
Creative Medical Technology Holdings (CELZ) Intangibles (2016 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Intangibles for 10 consecutive years, with $407230.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Intangibles fell 23.25% year-over-year to $407230.0; the TTM figure through Dec 2025 stood at $407230.0 (down 23.25% YoY), while the FY2025 annual figure was $407230.0, down 23.25% from the prior year.
- Intangibles climbed to $407230.0 in Q4 2025 per CELZ's latest filing, from $29747.0 in the prior quarter.
- Across five years, Intangibles topped out at $573721.0 in Q2 2021 and bottomed at $4084.0 in Q1 2021.
- Historically, Intangibles has averaged $313975.6 across 5 years, with a median of $421412.5 in 2022.
- Annual changes were most pronounced in 2021 — Intangibles plunged 99.03% — and 2022, when it soared 12256.95%.
- Creative Medical Technology Holdings' Intangibles stood at $31016.0 in 2021, then soared by 1304.42% to $435595.0 in 2022, then rose by 1.24% to $441011.0 in 2023, then gained by 20.31% to $530559.0 in 2024, then retreated by 23.25% to $407230.0 in 2025.
- Business Quant data shows CELZ's Intangibles at $407230.0 in Q4 2025, $29747.0 in Q3 2025, and $469240.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 93.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 355,459.00 |
| Mar 31, 2026 | 378,377.00 |
| Dec 31, 2025 | 407,230.00 |
| Sep 30, 2025 | 29,747.00 |
| Jun 30, 2025 | 469,240.00 |
| Mar 31, 2025 | 499,982.00 |
| Dec 31, 2024 | 530,559.00 |
| Sep 30, 2024 | 75,979.00 |
| Jun 30, 2024 | 87,464.00 |
| Mar 31, 2024 | 98,949.00 |
| Dec 31, 2023 | 441,011.00 |
| Sep 30, 2023 | 181,250.00 |
| Jun 30, 2023 | 389,553.00 |
| Mar 31, 2023 | 28,521.00 |
| Dec 31, 2022 | 435,595.00 |
| Sep 30, 2022 | 458,616.00 |
| Jun 30, 2022 | 481,637.00 |
| Mar 31, 2022 | 504,658.00 |
| Dec 31, 2021 | 31,016.00 |
| Sep 30, 2021 | 550,700.00 |